Recurrence of Dupuytren’s contracture: A consensus-based definition
نویسندگان
چکیده
PURPOSE One of the major determinants of Dupyutren disease (DD) treatment efficacy is recurrence of the contracture. Unfortunately, lack of agreement in the literature on what constitutes recurrence makes it nearly impossible to compare the multiple treatments alternatives available today. The aim of this study is to bring an unbiased pool of experts to agree upon what would be considered a recurrence of DD after treatment; and from that consensus establish a much-needed definition for DD recurrence. METHODS To reach an expert consensus on the definition of recurrence we used the Delphi method and invited 43 Dupuytren's research and treatment experts from 10 countries to participate by answering a series of questionnaire rounds. After each round the answers were analyzed and the experts received a feedback report with another questionnaire round to further hone in of the definition. We defined consensus when at least 70% of the experts agreed on a topic. RESULTS Twenty-one experts agreed to participate in this study. After four consensus rounds, we agreed that DD recurrence should be defined as "more than 20 degrees of contracture recurrence in any treated joint at one year post-treatment compared to six weeks post-treatment". In addition, "recurrence should be reported individually for every treated joint" and afterwards measurements should be repeated and reported yearly. CONCLUSION This study provides the most comprehensive to date definition of what should be considered recurrence of DD. These standardized criteria should allow us to better evaluate the many treatment alternatives.
منابع مشابه
Palmar fasciectomy after collagenase Clostridium histolyticum injection for Dupuytren’s contracture: A case report.
We present a case of successful salvage fasciectomy after initial collagenase Clostridium histolyticum (CCH) injection for the treatment of Dupuytren’s contracture. We did not find any remarkable scarring around the Dupuytren’s cord and nodule three and a half years after the initial CCH injection. Pathological findings revealed the previously ruptured cord and partial continuity of the collage...
متن کاملBasic Thoughts on Dupuytren’s Contracture
Dupuytren’s contracture has been known as such for nearly 200 years. It is a common disease in certain areas of the world. Patients suffering from the disease can have normal life expectancy. The natural course of the disease should be well known. However, our understanding of Dupuytren’s has grown little in the last 100 years despite the fact that it is easy to observe and over the years has b...
متن کاملARTICLE IN PRESS FEEDBACK INHIBITION OF HIGH TGF-b 1 CONCENTRATIONS ON MYOFIBROBLAST INDUCTION AND CONTRACTION BY DUPUYTREN’S FIBROBLASTS
Myofibroblasts and TGF-b1 are implicated in Dupuytren’s contracture. Transforming growth factor b1(TGF-b1) (1–10 ng/ml) increases myofibroblast induction in Dupuytren’s fibroblasts and contraction in a collagen model. However, higher doses (20–30 ng/ml) inhibit contraction in dermal fibroblasts. We hypothesized higher doses of TGF-b1 would inhibit induction of myofibroblasts and contraction by ...
متن کاملCollagenase clostridium histolyticum: a novel nonoperative treatment for Dupuytren’s disease
Dupuytren’s disease is a progressive disease of the palmar and digital fascial structures of the hand characterized by abnormal collagen deposition, nodular thickening of the palmar aponeurosis and subsequent joint contracture. Contracture occurs primarily at the metacarpophalangeal (MCP) and proximal interphalangeal (PIP) joint levels (Figure 1). Although pathologically benign, Dupuytren’s con...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
دوره 12 شماره
صفحات -
تاریخ انتشار 2017